Search Results

1 - 10 of 140 items :

  • "multiple myeloma" x
Clear All

References 1. Akar H, Seldin DC, Magnani B, et al. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid 2005; 12(4): 210-215. 2. Herrara GA(ed). The kidney in plasma cell dyscrasias Contrib Nephrol Basel Karger 2007; 153: 25-43. 3. Herrara GA(ed). The kidney in plasma cell dyscrasias Contrib Nephrol Basel Karger 2007; 153: 5-24. 4. Herrara GA(ed). The kidney in plasma cell dyscrasias Contrib Nephrol Basel Karger 2007; 153: 66-86. 5. Vieira-Leite-Segundo A, Lima Falcão MF, Correia-Lins Filho R, Multiple myeloma with

D, Lynch DP (eds). The mouth. Diagnosis and treatment. St Louis: Mosby, 1998; pp 212-236. 5. Van der Waal RIF, van de Scheur MR, Huijgens PC, Starink TM, van der Waal I . Amyloidosis of the tongue as a paraneoplastic marker of plasma cell dyscrasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod , 2002; 94:444-447. 6. Salisbury PL Jr, Jacoway JR . Oral amyloidosis: A late complication of multiple myeloma. Oral Surg , 1983; 56:48-50. 7. Angiero F, Seramondi R, Magistro S, Crippa R, Benedicenti S, Rizzardi C, Cattoretti G . Amyloid Deposition in the Tongue

REFERENCES 1. Provan D, Baglin T, Dokal I, et al. Oxford Handbook of Clinical Haematology, 4th ed. Oxford University Press, 2015; p. 336-361. 2. Palumbo A, Cerrato C. Diagnosis and therapy of multiple myeloma. Korean J Intern Med . 2013;28:263-273. 3. Bergsage D, Sprague C, Austin C, et al. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-Phenylalanine mustard (NC-8806). Cancer Chemotherapy Rep . 1962;21:87. 4. Rosignol L, Oriol A, Terulel A, et al. Superiority of bortezomib, thalidomide and dexamethasone as induction pre

: 2009, s. 56-57. 26. Walter-Croneck A. Angiogeneza. W: Dmoszyńska A. red., Szpiczak mnogi. Najnowsze metody rozpoznawania i leczenia. Warszawa; AN Media: 2009, s. 137, 140. 27. Jones D., Vichaya E. G., Wang X. S., Sailors M. H., Cleeland C. S., Wefel J. S. Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer, 2013, 119(23), 4188-4195. 28. Potrata B., Cavet J., Blair S., Howe T., Molassiotis, A. ‘Like a sieve’: an exploratory study on cognitive impairments in patients with multiple myeloma

References 1. Raab M S, Podar K, Breitkreutz I et al. Multiple myeloma. Lancet 2009; 374:324 - 339. 2. Joan Blade, Carlos Fernandez de Larrea, Laura Rosinol. Extramedullary involvement in multiple myeloma. Haematologica. 2012 Nov; 97(11): 1618-1619. 3. Blade J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jimenez R, Powles R. SoftTissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805-12. 4. Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, Potter MN, Ethell ME, Shaw BE

extramedullary hematopoiesis associated with multiple myeloma. Neurology 2013; 80 :1620. 11. NASR SH, ALOBEID BB, OTRAKJI JA, MARKOWITZ GS. Myeloma cast nephropathy, direct renal infiltration by myeloma, and renal extramedullary hematopoiesis. Kidney Int 2008; 73 :517-518.

REFERENCES 1. PALUMBO A, ANDERSON K. Multiple Myeloma . N Eng J Med. 2011; 364(11):1046-60. 2. HOWLADER N, NOONE AM, KRAPCHO M, GARSHELL J, MILLER D, ALTEKRUSE SF, et al . (eds) SEER Cancer Statistics Review, 1975-2011, National Cancer Institute Bethesda, MD, http://seercancergov/csr/1975_2011/ , based on November 2013 SEER data submission, posted to the SEER web site, April 2014. 3. KING AJ, GOODING S, RAMASAMY K. Managing multiple myeloma in the over 70s: A review . Maturitas. 2015; 80(2):148-54. 4. RAJKUMAR SV, DIMOPOULOS MA, PALUMBO A, BLADE J, MERLINI G

REFERENCES 1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood . 2008;111:2962-2972. 2. Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res . 2011;183:25-35. 3. Rajkumar SV. Multiple Myeloma. Curr Probl Cancer . 2009;33:7-64. 4. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer . 1975;36:842-854. 5. Hari PN, Zhang M-J, Roy V, et al. Is the international staging system superior to the Durie Salmon staging

References 1. Wright JH. A case of multiple myeloma. J Boston Soc Med Sci. 1900;4:195-204-5. 2. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3-9. 3. Wirk B. Renal failure in multiple myeloma: a medical emergency. Bone Marrow Transplant. 2011;46:771-83 4. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90. 5. Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic

REFERENCES Alt, J. R., Cleveland, J. L., Hannink, M., Diehl, J. A. (2000). Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Devel., 14 (24), 3102–3114. Athanasiou, E., Kaloutsi, V., Kotoula, V., Hytiroglou, P., Kostopoulos, I., Zervas, C., Kalogiannidis, P., Fassas, A., Christakis, J. I., Papadimitriou, C. S. (2001). Cyclin D1 Overexpression in Multiple Myeloma. Amer. J. Clin. Pathol., 116 , 535–542. Chang, H., Samiee, S., Yi. Q. L. (2006). Prognostic relevance of CD56 expression in